Hepatic Insufficiency Drug Development – Pipeline Analysis 2018 – ResearchAndMarkets.com

Hepatic Insufficiency Drug Development- Pipeline Analysis Report”

report has been added to ResearchAndMarkets.com’s

To assist investigators and funding and regulatory organizations, the
publisher has come up with a comprehensive report on Liver Failure
(Hepatic Insufficiency) pipeline. The report provides insights into
different therapeutic candidates in preclinical, research, discovery,
NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs
under development directly and through combination with other drugs are
also included.

Current status, developmental phase, participating companies and
entities, recent developments, orphan drug/ fast track/ other
designations, drug class are provided for each Liver Failure (Hepatic
Insufficiency) pipeline product. Mechanism of Action and the target area
of the pipeline product are also provided. Further, clinical and
preclinical trials along with results of the trials are also included in
the report.

In addition to complete details of each product, the report provides key
trends in Liver Failure (Hepatic Insufficiency) pipeline studies. The
products under development are categorized according to their
development phase, mechanism and company to provide detailed insights
into the type of drugs being developed and the stages of development.

Key Topics Covered

1 Hepatic Insufficiency Pipeline Analysis

2 Hepatic Insufficiency – Company Wise Pipeline Analysis

3 Hepatic Insufficiency R&D Pipeline Snapshots

4 Recent Developments in Hepatic Insufficiency Pipeline

5 Appendix

Companies Featured

  • Avexegen Therapeutics
  • BioLineRx
  • Cell2B
  • Glycosyn LLC
  • HepaRegeniX GmbH
  • Infant Bacterial Therapeutics
  • Leadiant Biosciences
  • Martin Pharmaceuticals
  • Mina Therapeutics
  • Novartis AG
  • PledPharma AB
  • ProMetic Life Sciences
  • Promethera Biosciences
  • Proterris Inc
  • Steminent Biotherapeutics Inc
  • Therapure Biopharma
  • Unicyte AG
  • Versantis AG
  • Vital Therapies Inc
  • Xenexus Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/research/m24rcn/hepatic?w=4


Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Drug